Artwork

内容由PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education提供。所有播客内容(包括剧集、图形和播客描述)均由 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Player FM -播客应用
使用Player FM应用程序离线!

Vivek Subbiah, MD - Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations in Colorectal, Pancreatic, and Other Cancers

1:18:32
 
分享
 

Manage episode 356695835 series 82214
内容由PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education提供。所有播客内容(包括剧集、图形和播客描述)均由 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Go online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel of experts in GI malignancies presents evidence-based guidance on modern diagnostic protocols and the personalized treatment of fusion-driven cancers. With relevant cases framing the discussion, the panel provides foundational knowledge on tumor-agnostic genomic alterations, updates on genomic testing techniques sensitive enough to capture rare alterations, and strategies for integrating targeted agents into treatment plans. Upon completion of this activity, participants should be better able to: Explain current guidelines and evidence related to molecular testing and targeted therapeutics, enabling timely diagnosis, and treatment of gene fusion–driven GI cancers; Implement collaborative, multidisciplinary genomic testing protocols designed to capture less common but actionable molecular alterations in metastatic or locally advanced GI cancers; and Construct safe, individualized treatment plans for patients with advanced GI cancers who present with uncommon genomic alterations
  continue reading

60集单集

Artwork
icon分享
 
Manage episode 356695835 series 82214
内容由PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education提供。所有播客内容(包括剧集、图形和播客描述)均由 PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal
Go online to PeerView.com/PCK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the modern era of personalized medicine, treatment of patients with advanced GI cancers has moved beyond a chemotherapy-centric model to one in which effective treatments can be matched to individual patients based on genomic testing results. What do colorectal and pancreatic cancer providers need to know about baseline testing and personalized treatment strategies, including those that target less common genomic mutations causing RET and NTRK alterations? In this activity, based on a recent live symposium, a panel of experts in GI malignancies presents evidence-based guidance on modern diagnostic protocols and the personalized treatment of fusion-driven cancers. With relevant cases framing the discussion, the panel provides foundational knowledge on tumor-agnostic genomic alterations, updates on genomic testing techniques sensitive enough to capture rare alterations, and strategies for integrating targeted agents into treatment plans. Upon completion of this activity, participants should be better able to: Explain current guidelines and evidence related to molecular testing and targeted therapeutics, enabling timely diagnosis, and treatment of gene fusion–driven GI cancers; Implement collaborative, multidisciplinary genomic testing protocols designed to capture less common but actionable molecular alterations in metastatic or locally advanced GI cancers; and Construct safe, individualized treatment plans for patients with advanced GI cancers who present with uncommon genomic alterations
  continue reading

60集单集

Semua episode

×
 
Loading …

欢迎使用Player FM

Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。

 

快速参考指南